| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print July 20, 2000
Dept. of Surgery, University of Liverpool, Liverpool L69 3GA
Corresponding Author: mboyd{at}liverpool.ac.uk
The MDM2 protein, through its interaction with p53 plays an important role in the regulation of the G1 checkpoint of the cell cycle. In addition to binding to and inhibiting the transcriptional activation function of the p53 protein, MDM2 binds, inter alia, to RB, and the E2F-1/DP-1 complex and in so doing may promote progression of cells into S-phase. Mice transgenic for MDM2 possess cells that have cell cycle regulation defects and develop an altered tumour profile independent of their p53 status. MDM2 also blocks the growth inhibitory effects of TGF-b1 in a p53 independent manner. We show here that a novel growth regulatory molecule is also the target of MDM2 mediated inhibition. Using a yeast two-hybrid screen we have identified a gene that encodes a novel cellular protein, MDM2 binding protein (MTBP), that binds to MDM2. MTBP can induce G1 arrest and this in turn can be blocked by MDM2. Our results suggest the existence of another growth control pathway that may be regulated, at least in part, by MDM2.
J. Biol. Chem, 10.1074/jbc.M004252200
Submitted on May 18, 2000
Revised on July 18, 2000
Accepted on July 19, 2000
A novel cellular protein MTBP binds to MDM2 and induces a G1 arrest that is suppressed by MDM2
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Maguire, P. C. Nield, T. Devling, R. E. Jenkins, B. K. Park, R. Polanski, N. Vlatkovic, and M. T. Boyd MDM2 Regulates Dihydrofolate Reductase Activity through Monoubiquitination Cancer Res., May 1, 2008; 68(9): 3232 - 3242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Giono and J. J. Manfredi Mdm2 Is Required for Inhibition of Cdk2 Activity by p21, Thereby Contributing to p53-Dependent Cell Cycle Arrest Mol. Cell. Biol., June 1, 2007; 27(11): 4166 - 4178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Koblish, S. Zhao, C. F. Franks, R. R. Donatelli, R. M. Tominovich, L. V. LaFrance, K. A. Leonard, J. M. Gushue, D. J. Parks, R. R. Calvo, et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo Mol. Cancer Ther., January 1, 2006; 5(1): 160 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E. Warburton, M. Brady, N. Vlatkovic, W. M. Linehan, K. Parsons, and M. T. Boyd p53 Regulation and Function in Renal Cell Carcinoma Cancer Res., August 1, 2005; 65(15): 6498 - 6503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Brady, N. Vlatkovic, and M. T. Boyd Regulation of p53 and MDM2 Activity by MTBP Mol. Cell. Biol., January 15, 2005; 25(2): 545 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-S. Dai and H. Lu Inhibition of MDM2-mediated p53 Ubiquitination and Degradation by Ribosomal Protein L5 J. Biol. Chem., October 22, 2004; 279(43): 44475 - 44482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Dai, S. X. Zeng, Y. Jin, X.-X. Sun, L. David, and H. Lu Ribosomal Protein L23 Activates p53 by Inhibiting MDM2 Function in Response to Ribosomal Perturbation but Not to Translation Inhibition Mol. Cell. Biol., September 1, 2004; 24(17): 7654 - 7668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wilsker, A. Patsialou, S. D. Zumbrun, S. Kim, Y. Chen, P. B. Dallas, and E. Moran The DNA-binding properties of the ARID-containing subunits of yeast and mammalian SWI/SNF complexes Nucleic Acids Res., February 24, 2004; 32(4): 1345 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Steinman, E. Burstein, C. Lengner, J. Gosselin, G. Pihan, C. S. Duckett, and S. N. Jones An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis J. Biol. Chem., February 6, 2004; 279(6): 4877 - 4886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Iwakuma and G. Lozano MDM2, An Introduction Mol. Cancer Res., December 1, 2003; 1(14): 993 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ganguli and B. Wasylyk p53-Independent Functions of MDM2 Mol. Cancer Res., December 1, 2003; 1(14): 1027 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bartl, J. Ban, H. Weninger, G. Jug, and H. Kovar A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene Nucleic Acids Res., February 15, 2003; 31(4): 1136 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Alarcon-Vargas and Z.'e. Ronai p53-Mdm2--the affair that never ends Carcinogenesis, April 1, 2002; 23(4): 541 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dang, M.-L. Kuo, C. M. Eischen, L. Stepanova, C. J. Sherr, and M. F. Roussel The RING Domain of Mdm2 Can Inhibit Cell Proliferation Cancer Res., February 1, 2002; 62(4): 1222 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Shcherbik, S. Kumar, and D. S. Haines Substrate proteolysis is inhibited by dominant-negative Nedd4 and Rsp5 mutants harboring alterations in WW domain 1 J. Cell Sci., January 3, 2002; 115(5): 1041 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zhang and C. Prives Cyclin A-CDK Phosphorylation Regulates MDM2 Protein Interactions J. Biol. Chem., August 3, 2001; 276(32): 29702 - 29710. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
